Mereo BioPharma said additional study data supported its plans to trial a treatment in children suffering from the bone disorder osteogenesis imperfecta. The company in November had reported disappointing results from a clinical trial of its treatment, called setrusumab. The treatment failed to achieve its primary endpoint of increasing bone density in the wrist. The study, however, achieved its 'secondary' endpoint of an increase in areal bone mineral density at the lumbar spine. On Tuesday, Mereo BioPharma said 'additional endpoint data' had built upon its previous findings, which it said 'demonstrated a dose-dependent, statistically significant bone building effect of setrusumab at multiple anatomical sites' in adult patients. 'We believe these additional endpoint data, together with the totality of the 12-month topline data and trend in fracture rate reduction in the high dose cohort, are fully supportive of moving forward with our planned pivotal trial in children with osteogenesis imperfecta,' chief medical officer Alastair MacKinnon said. At 12:58pm: (LON:MPH) Mereo Biopharma Group Ltd share price was +0.5p at 38.5p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.